{
    "clinical_study": {
        "@rank": "154771", 
        "biospec_descr": {
            "textblock": "whole blood"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "To compare the safety and efficacy of 12 months of low dose prednisone with low dose\n      cyclosporine combined with entecavir in patients with thrombocytopenia associated with\n      HBV-related cirrhosis."
        }, 
        "brief_title": "Observation Study of Prednisone and Cyclosporine in Treatment of Thrombocytopenia in Hepatitis B Cirrhosis", 
        "condition": [
            "Thrombocytopenia", 
            "Hepatitis B", 
            "Cirrhosis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B", 
                "Liver Cirrhosis", 
                "Fibrosis", 
                "Thrombocytopenia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  diagnosed HBV-associated cirrhosis\n\n          -  had an serum HBV DNA level of more than 500 IU per milliliter\n\n          -  have compensated liver cirrhosis\n\n          -  thrombocytopenia (defined as a platelet count of <30,000 per cubic millimeter)\n\n          -  accompanied with bleed tendency (including petechial, episxias, ecchymosis,\n             hemoptysis, hematemesis and hematochezia)\n\n          -  have a liver-biopsy specimen indicative of cirrhosis, ultrasonography and/or computed\n             tomographic imaging evidence of cirrhosis, or endoscopic evidence of portal\n             hypertension(splenomegaly, ascites, and esophageal varicose)\n\n        Exclusion Criteria:\n\n          -  pregnant\n\n          -  hepatocellular carcinoma\n\n          -  decompensated cirrhosis\n\n          -  coagulation function abnormal\n\n          -  had a history of other disease (e.g. aplastic anemia, autoimmune disease, idiopathic\n             thrombocytopenia et al) that could induced thrombocytopenia\n\n          -  co-infected with the human immunodeficiency virus\n\n          -  co-infected with hepatitis C virus\n\n          -  co-infected with hepatitis D virus\n\n          -  had a coexisting serious medical or psychiatric illness\n\n          -  serum creatinine level was more than 1.5 times the upper limit of the normal range"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Consecutive patients were enrolled from 15 centers in China from January 1, 2005 to\n        September 31, 2013."
            }
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01987791", 
            "org_study_id": "HBV-PLT-100"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Cyclosporins", 
                "Cyclosporine", 
                "Prednisone"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 13, 2013", 
        "number_of_groups": "1", 
        "official_title": "Comparison of Prednisone and Cyclosporine in the Treatment of Thrombocytopenia in Patients With Cirrhosis Associated With Hepatitis B in China: a Collaborative, Open-label, Real World Observational Study", 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": [
                "China: Food and Drug Administration", 
                "China: Ministry of Health"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The primary efficacy outcome was treatment failure, defined as the composite of (1) any platelet count below 50\u00d7109/L after four weeks treatment; (2) significant bleeding, defined as grade 2 severity from any anatomical site as per the ITP bleeding scale that defines bleed grades (0, none; 1, mild; or 2, marked) by objective criteria of 9, based on events that occurred since the last study visit; or (3) rescue treatment administered because of severe thrombocytopenia, bleeding, or a planned invasive procedure.", 
            "measure": "treatment failure", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01987791"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Secondary end points included proportion of patients with a complete platelet count response (platelet count of \u2265 100\u00d7109/L) without rescue treatment at 4 weeks, at 6 months , and at 12 months", 
                "measure": "proportion of patients with a complete platelet count response", 
                "safety_issue": "Yes", 
                "time_frame": "at 4 weeks, at 6 months , and at 12 months"
            }, 
            {
                "description": "Secondary end points included proportion of patients with an overall platelet count response (platelet count of \u2265 30\u00d7109/L with doubling from baseline) without rescue treatment at 4 weeks, at 6 months , and at 12 months", 
                "measure": "proportion of patients with an overall platelet count response", 
                "safety_issue": "Yes", 
                "time_frame": "at 4 weeks, at 6 months , and at 12 months"
            }
        ], 
        "source": "Peking University People's Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Peking University People's Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2005", 
        "study_design": "Observational Model: Case Control, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "November 2013"
    }
}